Hubei Goto Biopharm Co.Ltd.
Hubei Goto Biopharm Co.,Ltd., together with its subsidiaries, engages in the research, development, production, and sale of steroid drug raw materials in China and internationally. It offers starting materials, intermediates, and other pharmaceutical raw materials. The company was founded in 2006 and is based in Xiangyang, China.
Market Cap & Net Worth: Hubei Goto Biopharm Co.Ltd. (300966)
Hubei Goto Biopharm Co.Ltd. (SHE:300966) has a market capitalization of $327.75 Million (CN¥2.40 Billion) as of March 18, 2026. Listed on the SHE stock exchange, this China-based company holds position #15985 globally and #4255 in its home market, demonstrating a 1.51% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Hubei Goto Biopharm Co.Ltd.'s stock price CN¥20.86 by its total outstanding shares 115281113 (115.28 Million).
Hubei Goto Biopharm Co.Ltd. Market Cap History: 2021 to 2026
Hubei Goto Biopharm Co.Ltd.'s market capitalization history from 2021 to 2026. Data shows change from $640.89 Million to $327.75 Million (-18.32% CAGR).
Hubei Goto Biopharm Co.Ltd. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Hubei Goto Biopharm Co.Ltd.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.47x
Hubei Goto Biopharm Co.Ltd.'s market cap is 0.47 times its annual revenue
1728.56x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $640.89 Million | $590.89 Million | $78.33 Million | 1.08x | 8.18x |
| 2022 | $423.83 Million | $604.57 Million | $40.21 Million | 0.70x | 10.54x |
| 2023 | $360.57 Million | $566.40 Million | $23.01 Million | 0.64x | 15.67x |
| 2024 | $253.43 Million | $536.60 Million | -$27.59 Million | 0.47x | N/A |
Competitor Companies of 300966 by Market Capitalization
Companies near Hubei Goto Biopharm Co.Ltd. in the global market cap rankings as of March 18, 2026.
Key companies related to Hubei Goto Biopharm Co.Ltd. by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Hubei Goto Biopharm Co.Ltd. Historical Marketcap From 2021 to 2026
Between 2021 and today, Hubei Goto Biopharm Co.Ltd.'s market cap moved from $640.89 Million to $ 327.75 Million, with a yearly change of -18.32%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥327.75 Million | +5.94% |
| 2025 | CN¥309.36 Million | +22.07% |
| 2024 | CN¥253.43 Million | -29.71% |
| 2023 | CN¥360.57 Million | -14.93% |
| 2022 | CN¥423.83 Million | -33.87% |
| 2021 | CN¥640.89 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Hubei Goto Biopharm Co.Ltd. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $327.75 Million USD |
| MoneyControl | $327.75 Million USD |
| MarketWatch | $327.75 Million USD |
| marketcap.company | $327.75 Million USD |
| Reuters | $327.75 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.